NIFTY NINE IN NINETY NINE PLUS ONE Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (136)	1/16/1999 2:46:00 PM
From: Mike McFarland	Read Replies (2) of 613

My biotech prospects for next week: Of the stocks I own...ARIA and BTRN could do well next week. The volume on Ariad has stayed pretty decent after the epo spike and subsequent fall...I'm going to guess that the science is starting to sink in with investors (not that I am any judge of that, but I think I've read enough stuff to have a feel for it etc). Anyway, if the yahoo thread is visited by a lot of people maybe there will be less concern over any patent issues. This is the post from Yahoo to read (#643) messages.yahoo.com@m2.yahoo.com I made a bit of an ass of myself over there posting all kinds of junk...but a couple fellas posted some good stuff and resolved the whole patent thing as far as I am concerned. BTRN has been added to VD's model portfolio, I don't remember seeing any reason for the trade, but maybe MEDI hinted at favorable data at H&Q? From the stocks on my various watch lists I see GENE had three strong days in a row...also NGEN, REGN...and XOMA looked good Friday. As far as the genomic/bioinformatics (there has been a lot of discussion about GLGC lately)...of the big caps affx started strong last week with incy weak, they switched around toward the end of the week though. I noted that affx/aria did a deal for chips last week. I still haven't make up my mind whether I want to buy any of these...who knows, maybe if I get a better sense of what MSI is all about I'll just repurchase PCOP and go for combinatorial instead. I only made one trade last week, pretty happy about that--doing my best to cut back and deny my broker the easy money this year. --Mike The agreement will enable all Hoechst Marion Roussel drug innovation centers and the Hoechst-ARIAD Genomics Center (a joint venture of Hoechst Marion Roussel and ARIAD Pharmaceuticals (Nasdaq: ARIA-news) to access the Affymetrix gene expression monitoring technology as an integral component of their research and discovery efforts. The Hoechst-ARIAD Genomics Center utilizes functional genomics technologies to identify novel therapeutic targets and therapeutic proteins.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next